NLS Pharmaceutics Ltd. financial data

Symbol
NLSP, NLSPW on Nasdaq
Location
The Circle 6, 8058, Zurich, Switzerland
State of incorporation
Switzerland
Fiscal year end
December 31
Latest financial report
20-F - Q4 2023 - May 15, 2024

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 35.7M shares +10%
Common Stock, Shares, Outstanding 35.7M shares +10%
Common Stock, Value, Issued 733K USD +9.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 898K USD -90%
Assets, Current 1.82M USD -80.3%
Property, Plant and Equipment, Net 6.69K USD -63%
Other Assets, Noncurrent 16.9K USD +39.1%
Assets 1.85M USD -80.1%
Accounts Payable, Current 4.63M USD +95.2%
Accrued Liabilities, Current 1.65M USD +67.5%
Liabilities, Current 7.92M USD +136%
Liabilities 10.7M USD +78.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax -158K USD -211%
Retained Earnings (Accumulated Deficit) -70.4M USD -20.9%
Stockholders' Equity Attributable to Parent -8.83M USD -369%
Liabilities and Equity 1.85M USD -80.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Common Stock, Shares Authorized 35.7M shares +21.6%
Common Stock, Shares, Issued 35.7M shares +10%
Common Stock, Par or Stated Value Per Share 0.02 CHF/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 898K USD -90%
Deferred Tax Assets, Valuation Allowance 4.6M USD +22.7%
Deferred Tax Assets, Gross 1M USD -10.3%
Property, Plant and Equipment, Gross 39.6K USD 0%
Deferred Tax Assets, Operating Loss Carryforwards 4.34M USD +24.5%
Additional Paid in Capital 61M USD +0.27%